Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.46 |
| ▸ | KMO | O15229 | 3/20 | 0.45 |
| ▸ | WNT3A | P56704 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CCNC | P24863 | 1/20 | 0.39 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1032582 | 0.84 | PARP1 (0.50) | PARP1KMOALDH1A1LMNAALOX12 | |
| SCHEMBL1033122 | 0.81 | PARP1 (0.47) | PARP1KMOALDH1A1LMNAALOX12 | |
| SCHEMBL3151445 | 0.80 | PARP1 (0.61) | PARP1MAP4K4ALDH1A1LMNAALOX12 | |
| SCHEMBL1034439 | 0.79 | SIRT2 (0.50) | ALDH1A1LMNAHTT | |
| SCHEMBL1033211 | 0.78 | PARP1 (0.77) | PARP1ALDH1A1LMNAALOX12KDM4E | |
| SCHEMBL1033705 | 0.77 | PARP1 (0.51) | PARP1KMOALDH1A1LMNAALOX12 | |
| SCHEMBL27945291 | 0.77 | PARP1 (0.74) | PARP1ALDH1A1LMNAALOX12KDM4E | |
| SCHEMBL1033354 | 0.76 | PARP1 (0.60) | PARP1KMOALDH1A1LMNAALOX12 | |
| Hydrochloric Acid SCHEMBL27648173 | 0.75 | PARP1 (0.68) | PARP1ALDH1A1LMNAALOX12KDM4E | |
| SCHEMBL29412561 | 0.75 | PARP1 (0.72) | PARP1ALDH1A1ALOX12KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2273992-B1 | QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2016-05-25 | — | — | EP | disclosed |
| US-20110046110-A1 | QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2011-02-24 | — | — | US | disclosed |
| EP-2273992-A1 | QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009134973-A1 | QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046110-A1 | QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT3, SIRT1, SIRT2 | PARP1 183/4885MAP4K4 1524/4885FTO 2568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.